Should I buy Raffles Medical stock in 2025?
Is it the right time to buy Raffles Medical?
ScoreRaffles Medical Group, listed on the Singapore Exchange (SGX:BSL), is currently trading at approximately 1.00 SGD per share, with an average daily trading volume of 2.28 million shares. As one of Singapore’s largest private healthcare operators, Raffles Medical benefits from a robust sector backdrop driven by Asia’s demographic ageing and increasing demand for quality healthcare. Recent events include a dividend increase for 2024 and continued geographic expansion, especially into China and Vietnam, which reinforce management’s long-term growth ambitions. Although FY2024 saw a temporary dip in net profit and margins, revenues surpassed expectations, underlining ongoing market resilience. Technical indicators are decisively positive, with the stock trading above all major moving averages and receiving an ‘overall buy’ consensus from leading analysts. Notably, significant insider buying by the CEO has served as a strong indicator of management’s confidence. Market sentiment remains constructively optimistic, buoyed by consistent revenue growth, leadership in innovation, and a stable dividend yield. In this context, the consensus target price among more than 10 national and international banks stands at 1.30 SGD, highlighting perceived undervaluation in a sector poised for regional expansion. For investors seeking exposure to healthcare growth in Asia, Raffles Medical continues to offer an attractive and resilient investment profile.
- ✅Consistent revenue growth and geographic expansion across Asia.
- ✅Strong brand and leadership position in Singapore’s private healthcare sector.
- ✅Stable dividend yield of 2.51%, recently increased.
- ✅Low share price volatility (beta 0.32) supports defensive positioning.
- ✅Management confidence demonstrated by insider share purchases in 2024.
- ❌Recent net margin decline may impact short-term profitability.
- ❌Significant exposure to Asian markets and evolving regional regulation.
Score- ✅Consistent revenue growth and geographic expansion across Asia.
- ✅Strong brand and leadership position in Singapore’s private healthcare sector.
- ✅Stable dividend yield of 2.51%, recently increased.
- ✅Low share price volatility (beta 0.32) supports defensive positioning.
- ✅Management confidence demonstrated by insider share purchases in 2024.
Is it the right time to buy Raffles Medical?
- ✅Consistent revenue growth and geographic expansion across Asia.
- ✅Strong brand and leadership position in Singapore’s private healthcare sector.
- ✅Stable dividend yield of 2.51%, recently increased.
- ✅Low share price volatility (beta 0.32) supports defensive positioning.
- ✅Management confidence demonstrated by insider share purchases in 2024.
- ❌Recent net margin decline may impact short-term profitability.
- ❌Significant exposure to Asian markets and evolving regional regulation.
Score- ✅Consistent revenue growth and geographic expansion across Asia.
- ✅Strong brand and leadership position in Singapore’s private healthcare sector.
- ✅Stable dividend yield of 2.51%, recently increased.
- ✅Low share price volatility (beta 0.32) supports defensive positioning.
- ✅Management confidence demonstrated by insider share purchases in 2024.
- What is Raffles Medical?
- What is the Raffles Medical stock price?
- Our full analysis of Raffles Medical stock
- How to buy Raffles Medical stock in Singapore?
- Our 7 tips for buying Raffles Medical stock
- The latest news about Raffles Medical
- FAQ
- On the same topic
Why trust HelloSafe ?
At HelloSafe, our expert has been tracking the performance of Raffles Medical for over three years. Every month, hundreds of thousands of users in Singapore trust us to analyse market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by Raffles Medical.
What is Raffles Medical?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | Singapore | Singapore headquarters, reflecting a focus on local and regional healthcare markets. |
| 💼 Market | Singapore Exchange (SGX) | Listed on the main board, providing high level of transparency and market liquidity. |
| 🏛️ ISIN code | SG1CH4000003 | Unique identifier for Raffles Medical shares, necessary for international transactions. |
| 👤 CEO | Dr. Loo Choon Yong | Founder and long-time leader, signaling vision and stability in company strategy. |
| 🏢 Market cap | SGD 1.85 billion | Demonstrates Raffles Medical’s significant market presence among SG healthcare stocks. |
| 📈 Revenue | SGD 752.4 million (2024) | Revenue grew by 6.3% year-on-year, reflecting resilient demand and successful expansion. |
| 💹 EBITDA | SGD 129.82 million | Strong EBITDA level points to effective cost control and robust operating performance. |
| 📊 P/E Ratio (Price/Earnings) | 30.24 | Indicates a premium valuation, but highlights strong growth expectations and market trust. |
What is the Raffles Medical stock price?
The price of Raffles Medical stock is rising this week. Currently trading at S$1.00, the share has seen a 0.99% decrease over the past 24 hours, but a weekly gain of 0.50%. Raffles Medical holds a market capitalisation of S$1.85 billion, with an average three-month trading volume of 2.28 million shares. Its price-to-earnings (P/E) ratio stands at 30.24, offering a dividend yield of 2.51%, and it shows low volatility with a beta of 0.32. This stable profile presents Raffles Medical as a compelling healthcare investment for Singapore-focused portfolios.
Our full analysis of Raffles Medical stock
After a comprehensive review of Raffles Medical’s latest financial results and a thorough evaluation of its stock performance over the past three years, we have leveraged a multi-source approach that synthesizes financial indicators, technical signals, market trends, and the positioning of industry competitors through our proprietary algorithmic models. The findings point toward renewed interest in the healthcare sector across Asia, where private providers are primed for further growth. So, why might Raffles Medical stock once again become a strategic entry point into the Asian healthcare sector in 2025?
Recent performance and market context
Raffles Medical stock is currently trading at S$1.00 (as of July 7, 2025), exhibiting resilience amid global equity volatility. Over the last six months, its share price has appreciated by an impressive 19.05%, thanks to consistent operational performance and an increasingly favorable regional context. Despite a slight year-on-year price dip of 0.99%, the company has maintained stability, outperforming several regional peers. Notable recent events include an increased dividend for 2024 and significant insider buying, including substantial share repurchases by the CEO, enhancing investor confidence. The company’s ongoing strategic push in China and Southeast Asia—coupled with demographic tailwinds from Asia’s ageing population—create strong demand prospects for private healthcare over the coming years. These positive developments are further supported by Singapore’s robust, innovation-driven healthcare system and a growing middle class willing to pay for quality care—a climate where Raffles Medical, with its reputable brand, is uniquely positioned to thrive.
Technical analysis
The latest technical signals reinforce a constructive outlook. The stock’s Relative Strength Index (RSI) sits at 62.09, in the neutral-to-bullish zone, indicating sustained buying pressure without reaching overbought extremes. The MACD has turned marginally negative at -0.01, but remains close to the axis, suggesting near-term consolidation rather than a bearish turn. Moving averages are sharply supportive: the 20-, 50-, 100-, and 200-day averages all issue a buy signal, underscoring short- and medium-term upward momentum. Key price support levels are established at S$0.95, with the next technical resistance at S$1.02—a break above which could trigger further upside. The technical consensus, with 12 bullish signals from major moving averages, positions the stock as a strong candidate for renewed accumulation.
Fundamental analysis
On the fundamentals, Raffles Medical demonstrates sound revenue growth and prudent financial management. Revenue for 2024 climbed to S$752.4 million (+6.3% vs. 2023), outpacing analyst expectations and reflecting robust demand across its clinics and hospitals. While net profit fell to S$62.2 million (in part due to strategic investments and margin compression to 8.3%), the company remains solidly profitable. Crucially, Raffles Medical maintains a healthy EBITDA of S$129.8 million and an earnings per share of S$0.034. The stock trades at a price/earnings ratio of 30.24, which, given its market leadership, regional expansion, and low beta (0.32: indicating stability), can be justified within the context of a growth sector. Moreover, the dividend yield stands at 2.51%, offering investors attractive income in addition to capital appreciation potential. Structural strengths including a well-diversified pan-Asian network—with over 100 clinics, market leadership in private healthcare, and a respected, trusted brand—suggest the company is well equipped for long-term growth, both organically and through strategic expansion.
Volume and liquidity
Trading volumes remain robust, with a three-month daily average of 2.28 million shares, reflecting continued institutional and retail interest in the name. This sustained activity fosters liquidity, which in turn supports dynamic valuation and allows for flexible entry and exit opportunities. Raffles Medical’s free float is sufficiently high to contain volatility, yet the insider buying trend signals management’s confidence in future prospects—an important market signal that further enhances credibility and perceived value among investors.
Catalysts and positive outlook
Looking ahead, several bullish catalysts stand out. First, the company’s S$0.025 per share dividend underscores management’s commitment to shareholder returns. Second, CEO-led share increases reiterate insider conviction and align leadership interests with shareholders. Third, the strategic pivot into China and Vietnam is already delivering incremental top-line growth and positions the company to benefit from rising regional demand for quality healthcare, underpinned by demographic trends and healthcare reforms. Raffles Medical’s leadership in digital health—through telemedicine expansion and innovative patient care platforms—reinforces its ability to capture new revenue streams and defend market share in an increasingly tech-savvy landscape. Furthermore, the company’s reputation as an ESG-conscious provider, paired with its diversified presence and integrated model (including hospitals, clinics, and medical insurance), offers resilience and optionality amid industry shifts. The targeted annual profit growth rate near 10%, as projected by consensus, evidences robust forward momentum. With further sector consolidation and ongoing regulatory support for private healthcare, Raffles Medical’s prospects remain highly constructive.
Investment strategies
- Short-term: Technical indicators suggest near-term upward momentum, with the S$1.02 resistance a potential breakout level. Traders may find opportunities in tactical entries on pullbacks toward the S$0.95–S$1.00 support zone, taking advantage of bullish sentiment and increased institutional flow.
- Medium-term: Positive sector fundamentals, healthy volume, and the prospect of new product or service launches may drive multiple re-rating events. Investors positioned ahead of catalyst events—such as earnings reports or regulatory changes—may enjoy outsized returns.
- Long-term: The company’s market leadership, recurring revenue from diversified healthcare operations, and ongoing expansion (especially in China, Vietnam, and via digital health channels) underpin a compelling compounding story for patient, growth-oriented investors. Dividend accrual and sector rotation into quality defensive names further enhance the risk/reward profile.
Is it the right time to buy Raffles Medical?
In summary, Raffles Medical offers a rare blend of stability, growth, and strategic advantage in an attractive Asian healthcare market. Its consistent revenue growth, robust trading liquidity, expanding geographic footprint, and commitment to shareholder value justify renewed interest from both institutional and retail investors. The low beta and attractive dividend yield further cement its status as a core holding for those seeking resilient, long-duration exposure to healthcare innovation in Asia. With the company already showing a +19% price increase over six months, and set to benefit from demographic, regulatory, and technological trends, the case for serious consideration is compelling. Raffles Medical appears to be entering a new bullish phase, where fundamentals and market momentum converge to create a timely, high-quality opportunity for active and long-term investors alike.
How to buy Raffles Medical stock in Singapore?
Buying Raffles Medical stock online is straightforward and secure when you use a MAS-regulated broker in Singapore. You can invest either by purchasing actual shares (spot buying) and becoming a shareholder, or by trading Contracts for Difference (CFDs), which allows you to speculate on price changes without owning the stock. Both methods offer flexibility and can be completed in just a few clicks. To help you choose, a broker comparison is available further down the page.
Cash buying
A cash purchase means you directly buy Raffles Medical shares on the Singapore Exchange and are registered as the owner. Typically, local brokers charge a fixed commission per order, often around SGD 5 per trade.
Gain scenario
If the Raffles Medical share price is SGD 1.00, you can buy around 995 shares with a SGD 1,000 stake, including a brokerage fee of around SGD 5.
If the share price rises by 10%, your shares are now worth SGD 1,100.
Result: +SGD 100 gross gain, i.e. +10% on your investment.
Trading via CFD
CFD trading lets you speculate on Raffles Medical share price movements, using leverage so you can gain greater exposure than your initial outlay. Here, you do not own the actual shares. Instead, you pay a spread (the broker’s price difference) and may also incur overnight financing costs if you hold positions for more than a day.
Example of a CFD Gain Scenario
You open a CFD position on Raffles Medical shares, with 5x leverage and a SGD 1,000 stake.
This gives you a market exposure of SGD 5,000.
✔️ Gain scenario:
If the stock rises by 8%, your position gains 8% × 5 = 40%.
Result: +SGD 400 gain, on a bet of SGD 1,000 (excluding fees).
Final advice
Before you start investing, always compare the fees, trading conditions, and services offered by different online brokers. Your choice between spot buying or CFD trading depends on your goals and risk appetite. To help you decide, a detailed broker comparison awaits further down the page.
Check out the best brokers in Singapore!Compare brokersOur 7 tips for buying Raffles Medical stock
| 📊 Step | 📝 Specific tip for Raffles Medical |
|---|---|
| Analyze the market | Review healthcare sector trends and Raffles Medical’s performance on the SGX over the last 12 months. |
| Choose the right trading platform | Pick a MAS-licensed online broker offering competitive fees and seamless access to SGX-listed stocks. |
| Define your investment budget | Decide how much to invest in Raffles Medical, balancing healthcare exposure with your wider SG portfolio. |
| Choose a strategy (short or long term) | Consider a medium- to long-term approach, leveraging Raffles Medical’s sector leadership and regional expansion. |
| Monitor news and financial results | Track announcements, quarterly earnings, and expansion updates that could influence the stock’s outlook. |
| Use risk management tools | Set stop-loss orders and take-profit levels to manage swings in Raffles Medical’s share price. |
| Sell at the right time | Reassess your position during peak valuations or ahead of major market-moving health sector events. |
The latest news about Raffles Medical
Raffles Medical announces a SGD 0.025 per share dividend for 2024, reflecting strong operational cash flows. The recent dividend increase, approved by the board in July 2025, confirms the company’s confidence in its earnings quality and long-term strategy. The payout underscores stable financial management despite margin pressures and is particularly relevant for investors seeking steady income in the Singapore equity market.
Raffles Medical’s stock rises 0.5% over the last week, continuing a positive six-month trend. The share price has shown resilience with a 19.05% gain over the last six months, attracting sustained trading volumes on the Singapore Exchange. This trend indicates growing investor confidence in the company’s expansion and growth prospects, supported by local and regional healthcare demand.
Technical analysis signals point to a strong “buy” consensus, with 12 upward signals on key moving averages. Recent technical reviews highlight buy signals from the 20-day, 50-day, 100-day, and 200-day moving averages. These technical indicators suggest a favorable entry window and continued bullish momentum, important for Singapore-based institutional and retail participants.
Raffles Medical advances in regional expansion, including ongoing growth in China and Southeast Asia. Strategic updates in the last week confirm continued investment in overseas clinics and medical partnerships. This expansion diversifies revenue sources and strengthens Raffles Medical's market position, providing additional growth levers beyond the Singapore market.
Leadership stability is reinforced by significant insider share purchases by the CEO, Dr. Loo Choon Yong. Recent filings show new insider buying activity, signaling strong management commitment and alignment with shareholders. Such actions strengthen corporate governance and are typically regarded as a vote of confidence by market participants in Singapore.
FAQ
What is the latest dividend for Raffles Medical stock?
Raffles Medical currently pays a dividend. The most recent dividend declared was SGD 0.025 per share for 2024, typically paid after the company’s annual meeting in the second quarter. This dividend reflects a yield of around 2.5% at recent share prices. The company has a track record of consistent annual distributions and a focus on rewarding shareholders as part of its growth strategy.
What is the forecast for Raffles Medical stock in 2025, 2026, and 2027?
Based on current estimates, projected prices are SGD 1.30 by end-2025, SGD 1.50 by end-2026, and SGD 2.00 by end-2027. Raffles Medical benefits from robust healthcare demand in Singapore and Asia, along with continued expansion into China and new digital health services, supporting potential price appreciation.
Should I sell my Raffles Medical shares?
Holding onto Raffles Medical shares can be considered sound given its strong local brand, stable financials, and sector leadership. The current valuation is supported by resilient demand for private healthcare and prudent company management. With further regional expansion and projected earnings growth, maintaining a position appears appropriate for medium- to long-term investors.
Are Raffles Medical shares eligible for tax-free capital gains or dividends in Singapore?
Yes, Singapore does not tax capital gains or dividends for individual investors on locally listed shares, including Raffles Medical. You receive dividends in full with no withholding for Singapore residents. This fiscal environment makes local equity investing particularly attractive from a tax perspective.
What is the latest dividend for Raffles Medical stock?
Raffles Medical currently pays a dividend. The most recent dividend declared was SGD 0.025 per share for 2024, typically paid after the company’s annual meeting in the second quarter. This dividend reflects a yield of around 2.5% at recent share prices. The company has a track record of consistent annual distributions and a focus on rewarding shareholders as part of its growth strategy.
What is the forecast for Raffles Medical stock in 2025, 2026, and 2027?
Based on current estimates, projected prices are SGD 1.30 by end-2025, SGD 1.50 by end-2026, and SGD 2.00 by end-2027. Raffles Medical benefits from robust healthcare demand in Singapore and Asia, along with continued expansion into China and new digital health services, supporting potential price appreciation.
Should I sell my Raffles Medical shares?
Holding onto Raffles Medical shares can be considered sound given its strong local brand, stable financials, and sector leadership. The current valuation is supported by resilient demand for private healthcare and prudent company management. With further regional expansion and projected earnings growth, maintaining a position appears appropriate for medium- to long-term investors.
Are Raffles Medical shares eligible for tax-free capital gains or dividends in Singapore?
Yes, Singapore does not tax capital gains or dividends for individual investors on locally listed shares, including Raffles Medical. You receive dividends in full with no withholding for Singapore residents. This fiscal environment makes local equity investing particularly attractive from a tax perspective.
On the same topic
